Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › oxaliplatin

oxaliplatin

17 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of oxaliplatin

188 trials tracked of oxaliplatin: 33 in phase 3 or 4 and 17 with published results. The most-cited published study has 685 citations.

188Trials tracked
33Phase 3 & 4
0Recruiting
17With published results
Phase distribution
Phase 4 3 Phase 3 30 Phase 2 138 Phase 1 12 Other / NA 5
  1. Phase 3 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811) Completed · 685 cited
  2. Phase 3 Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859) Completed · 607 cited
  3. Phase 3 A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment Completed · 431 cited
  4. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585) Completed · 334 cited
  5. Phase 3 A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma Completed · 286 cited
  6. Phase 3 A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients Completed · 257 cited
Show 44 more trials
  1. Phase 3 Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Completed · 235 cited
  2. Phase 3 Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) Completed · 222 cited
  3. Phase 3 Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer Completed · 212 cited
  4. Phase 3 An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread Completed · 67 cited
  5. Phase 3 Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Completed · 42 cited
  6. Phase 3 Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer Completed · 34 cited
  7. Phase 4 A Translational Study of Bevacizumab in Participants With Metastatic Colorectal Cancer Completed · 18 cited
  8. Phase 3 Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors Completed · 16 cited
  9. Phase 3 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Completed · 14 cited
  10. Phase 3 Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Gastric, or Gastroesophageal Junction Carcinoma Completed · 7 cited
  11. Phase 3 Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer Completed
  12. Phase 4 A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum Completed
  13. Phase 4 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed
  14. Phase 3 Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  15. Phase 3 Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer Completed
  16. Phase 3 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension Completed
  17. Phase 3 A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Completed
  18. Phase 3 Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer Completed
  19. Phase 3 Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL) Completed
  20. Phase 3 LOGiC - Lapatinib Optimization Study in ErbB2 (HER2) Positive Gastric Cancer: A Phase III Global, Blinded Study Designed to Evaluate Clinical Endpoints and Safety of Chemotherapy Plus Lapatinib Completed
  21. Phase 3 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed
  22. Phase 3 Cetuximab, Bevacizumab & 5FU/Leucovorin vs. Oxaliplatin, Bevacizumab & 5FU/Leucovorin in Metastatic Colorectal Cancer Completed
  23. Phase 3 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial Completed
  24. Phase 3 A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer Completed
  25. Phase 3 Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer Completed
  26. Phase 3 Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer Completed
  27. Phase 3 A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer Completed
  28. Phase 2 Combination Chemotherapy in Treating Patients With Previously Untreated Stage II or Stage III Esophageal Cancer That Can Be Removed By Surgery Completed
  29. Phase 2 Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer Completed
  30. Phase 2 A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer. Completed
  31. Phase 2 A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC) Completed
  32. Phase 2 A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Completed
  33. Phase 2 Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin as 2nd Line Therapy for Non-Hodgkin's Lymphoma (NHL) Completed
  34. Phase 2 Sorafenib + mFOLFOX for Hepatocellular Carcinoma Completed
  35. Phase 2 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma Completed
  36. Phase 2 FOLFOXIRI Plus Panitumumab Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only Completed
  37. Phase 2 Combination Chemotherapy, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer Completed
  38. Phase 2 Docetaxel & Oxaliplatin in Combination With Bevacizumab as First-Line Treatment in Subjects With Non-Small Cell Lung Cancer (NSCLC) Completed
  39. Phase 2 A Pilot Study of Pre- and Post-surgery Chemotherapy With mFOLFIRINOX in Localized, Resectable Pancreatic Adenocarcinoma Completed
  40. Phase 2 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed
  41. Phase 2 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction Completed
  42. Phase 2 Second Line ColoRectal Cancer Therapy in Combination With Combination of FOL- Folinic Acid(Leucovorin), F - Fluorouracil and OX - Oxaliplatin (FOLFOX) Completed
  43. Phase 2 Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer Completed
  44. Phase 2 Study of Oxaliplatin, Capecitabine and Bevacizumab as First Line Treatment for Patients With Advanced Colorectal Cancer Completed

Showing the 50 most-cited and recently-updated of 188 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Oxaliplatin addition to rectal cancer chemoradiation improves tumor regression
Gastroenterology RCT
Oxaliplatin addition to rectal cancer chemoradiation improves tumor regression Adding oxaliplatin to radiation helps tumor shrink but does not improve long-term survival for high-risk rectal cancer patients
Adding oxaliplatin to capecitabine chemoradiation for high-risk rectal cancer significantly improved tumor regression rates, but did not enh…
Adding oxaliplatin to standard radiation therapy helped tumors shrink more in high-risk rectal cancer patients, yet it did not improve long-…
Jun 2, 2026
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Oncology RCT
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
May 16, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis
Oncology Sys. Review
Case report and literature review on oxaliplatin and tegafur for AEG with intramural metastasis A rare cancer spread inside the esophagus wall needs careful treatment plans for older adults
This case report and literature review examines a 77-year-old male with adenocarcinoma of the esophagogastric junction and esophageal intram…
A doctor reviewed a rare case where cancer spread inside the esophagus wall. This condition often means the disease is already in the body. …
Frontiers May 11, 2026
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct
Dermatology Sys. Review
Review of case report suggests multimodal therapy potential for unresectable intraductal papillary mucinous neoplasms of the bile duct At-a-Glance
This review of a case report describes two patients with unresectable intraductal papillary mucinous neoplasms of the bile duct treated with…
A new three-drug combination shrank a rare bile duct tumor in one patient and stopped another from growing, offering hope for a cancer with …
Frontiers May 8, 2026
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
Oncology Meta-analysis
Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors New analysis shows pucotenlimab improves outcomes for several solid tumor types
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
May 1, 2026
S-1 plus oxaliplatin consolidation shows low toxicity in stage II/III lower rectal cancer patients
Oncology Phase I
S-1 plus oxaliplatin consolidation shows low toxicity in stage II/III lower rectal cancer patients First study reports SOX consolidation for lower rectal cancer
This Phase I study enrolled 12 patients with stage II/III lower rectal adenocarcinoma.
A small early trial found SOX chemotherapy was safe after radiation for lower rectal cancer, with surgery completed on time for all patients…
May 1, 2026
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients
Oncology RCT
Neoadjuvant mFOLFOXIRI plus bevacizumab reduces peritoneal tumor burden in colorectal cancer patients Chemo before surgery may reduce tumor burden in colorectal cancer patients
This phase II randomized controlled trial evaluated 53 patients with resectable peritoneal metastasis of colorectal cancer.
A trial suggests chemo before surgery might lower tumor markers for colorectal cancer patients with spread to the abdomen.
Apr 28, 2026
Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort
Oncology Cohort
Machine learning model predicted FOLFIRINOX dose modifications in pancreatic ductal adenocarcinoma cohort Most patients on strong pancreatic cancer chemo needed a dose change
This cohort study included 514 patients with pancreatic ductal adenocarcinoma treated at UCSF oncology clinics.
Over 60% of patients with pancreatic cancer needed a dose adjustment during treatment with FOLFIRINOX at UCSF clinics.
medRxiv Apr 28, 2026
Tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients
Oncology RCT
Tumor debulking plus chemotherapy did not improve overall survival in multiorgan metastatic colorectal cancer patients Surgery Doesn’t Extend Life for Advanced Colon Cancer
This randomized clinical trial enrolled 382 adult patients with multiorgan metastatic colorectal cancer across 27 hospitals in the Netherlan…
This large study shows that removing tumors in advanced colon cancer doesn’t help people live longer.
JAMA Apr 23, 2026
Case report describes sintilimab-associated toxic epidermal necrolysis in gastric carcinoma patient
Oncology Sys. Review
Case report describes sintilimab-associated toxic epidermal necrolysis in gastric carcinoma patient Rare Skin Reaction Follows Successful Stomach Cancer Therapy
This case report details a patient with gastric carcinoma developing delayed-onset toxic epidermal necrolysis during neoadjuvant sintilimab …
A new case shows a common stomach cancer drug can cause dangerous skin reactions even after surgery.
Frontiers Apr 22, 2026
Case report and literature review of ENKTL presenting with ocular symptoms and treated with GemOx
Hematology Sys. Review
Case report and literature review of ENKTL presenting with ocular symptoms and treated with GemOx A Rare Eye Symptom Led Doctors Down the Wrong Path for Months
This case report and literature review describes a single patient with extranodal natural killer/T cell lymphoma presenting with ocular symp…
Double vision and sinus scans that looked clean hid a rare lymphoma that stole a man's sight after months of wrong treatments.
Frontiers Apr 18, 2026

All oxaliplatin Articles